Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies

Table 1 Basic demographic and anamnestic data as well as questionnaire scores at V1

	All Patients	CGRP-receptor mAb-group	CGRP mAb group
N	61	29	32
Age (years)	49.97 ± 11.28	50.55 ± 12.82	49.44 ± 9.86
Sex (female)	59 (96.7%)	28 (96.6%)	31 (96.1%)
Chronic migraine	40 (65.6%)	17 (58.6%)	23 (71.9%)
Months of treatment before discontinuation	9.64 ± 1.14	9.69 ± 1.37	9.59 ± 0.91
MMD	8.59 ± 6.60	9.41 ± 5.92	7.84 ± 7.17

Data for all patients and both subgroups (CGRP-receptor mAb and CGRP mAb group). Data expressed as mean ± standard deviation or absolute number (%). MMD = monthly migraine days.

ISSN: 1129-2377